News

Clinical trial with Gilteritinib for patients with FLT3/ITD-positive AML opens in Freiburg
14.12.2020

In September 2020, a phase I/II trial with Gilteritinib (ASP2215) for the treatment of children, adolescents and young adults with a FLT3/ITD-positive refractory or progressive AML has been launched at the center Freiburg.
Read the article

no articles available

Presseinformationen

In Kürze finden Sie hier aktuelle Pressemeldungen des Forschungsverbunds GPOH Südwest. Gerne können Sie bei Interesse auch direkt Kontakt mit uns aufnehmen.

contact

Privacy Notice

To improve our website and provide you with a great experience, we use cookies and tracking methods on our site. In the privacy settings, you can see which services we use and decide for yourself at any time, even by subsequently changing your settings, whether and to what extent you want to consent to these services.

Necessary cookies are always loaded

Analysis-/Marketing Cookies

Load external components

Show details

Imprint

News

Clinical trial with Gilteritinib for patients with FLT3/ITD-positive AML opens in Freiburg

Presseinformationen

Privacy Notice